这些创新药公司立功,二季报揭示领跑主动权益药基新标的

红刊财经
19 Jul

7月第三周,内地公募基金二季报披露渐入高潮,在年内主动权益类基金纷纷飘红时,二季度他们调仓或者建仓了哪些公司成为焦点,不仅是老牌明星基金经理的新思,而且年内领跑基金的组合变化更为引人关注,最新排在前列的多为受益于 创新药 的药基。截至7月14日收盘,在2025年内地主动权益类公募排名中,暂时有5只基金的年内净值增长率超过80%,其中除去半年度排名居首的 中信建投 北交所精选外,其余的四只基金均为...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10